Carlos F. D. L.
- Country
- Spain
- Department
- Hematology
Research Overview
- Evaluation of Humanized CAR T-Cell Therapy ARI0002h Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulators, and Anti-CD38 Antibody
- Pharmacokinetic Comparability Study of Pre- and Post-change Teclistamab in Relapsed/Refractory Multiple Myeloma Patients
- AZD0120 Versus Standard Regimens in Relapsed or Refractory Multiple Myeloma: A Phase III Randomised Study
Data & Insights
Has run more than one trial at 155 of 290 partner sites.
Specializations
Multiple Myeloma Management
This investigator specializes in treating multiple myeloma across various disease stages, with particular emphasis on newly diagnosed cases and relapsed/refractory multiple myeloma.
- Treatment-naive multiple myeloma
- High-risk smoldering multiple myeloma
- Post-transplant therapy optimization
Their research encompasses both transplant-eligible and transplant-ineligible patient populations.
Novel Therapeutic Approaches
The investigator focuses on evaluating innovative treatments including bispecific antibodies and CAR-T cell therapy for multiple myeloma.
- Elranatamab studies
- Ciltacabtagene autoleucel therapy
- Linvoseltamab investigations
Their work includes assessment of combination therapies with established treatments.
Additional Research Areas
The investigator's expertise extends to related B-cell malignancies and plasma cell disorders.
- Waldenstrom Macroglobulinemia
- Light-chain amyloidosis
- Comparative treatment efficacy studies
Their research includes evaluation of novel therapeutic combinations and treatment sequences.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.